

Study Title: Pharmacodynamic Biomarkers to Support Biosimilar Development:
Clinical Study 2 (PCSK9 Inhibitors – Alirocumab and Evolocumab)

Document Title: Informed Consent Form – Study No. SCR-007

Document Date : 21 May 2020

NCT Number: NCT04189484

**CONSENT TO TAKE PART IN A CLINICAL RESEARCH STUDY
AND
AUTHORIZATION TO DISCLOSE HEALTH INFORMATION**

Sponsor/Study Title: US Food and Drug Administration, “Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 2”

Protocol Number: SCR-007

Principal Investigator: Colleen Nalepinski MPAS, PA-C
**(Investigator
Study Physician:** Carlos Sanabria, MD.

Telephone: (800) 597-4507
(855) 622-8100 (24-Hour)

Address: Spaulding Clinical Research, LLC
525 S Silverbrook Dr.
West Bend, WI 53095

SUBJECT SCREENING # _____

Please read this form carefully. Take time to ask the study investigator or study staff as many questions about the study as you would like. The study investigator or study staff can explain words or information that you do not understand. Reading this form and talking to the study investigator or study staff may help you decide whether to take part or not. If you decide to take part in this study, you must sign your name and date at the end of this form. You cannot take part in this research study until you sign and date this form.

WHAT IS A VOLUNTEER INFORMED CONSENT?

Please read this consent form carefully. This consent form provides important information about participating in a research study to help you decide whether or not you would like to participate as a research subject. This form contains important information about what you will be asked to do during the study, about the risks and benefits of the study, and about your rights as a research subject. You may discuss your decision with your family, your friends and/or your investigator. Take time to ask the study investigator or research team as many questions about the study as you would like. The study investigator or research team can explain words or information that you do not understand. If you decide to take part in this study, you must sign your name and date at the end of this form. Your participation is entirely voluntary. If you choose to participate you can change your mind at any time and withdraw from the study. You will not be penalized in any way or lose any benefits to which you would otherwise be entitled if you choose not to participate in this study or if you choose to withdraw. You cannot take part in this research study until you sign and date this form. A copy of the signed and dated form will be provided to you for your record.

You are being asked to take part in a research study of two biological drugs: Evolocumab and Alirocumab in injection form. Evolocumab and Alirocumab have both been approved by the U.S. Food and Drug Administration (FDA) for treatment of high cholesterol, and it is known they are safe and well tolerated. The information collected in this study will be used to inform the design of future clinical pharmacology studies for study drugs that may be biosimilar (highly similar) to Evolocumab or Alirocumab. Before you

decide to take part, you should understand the possible benefits and risks associated with this study. This process is known as informed consent and means that you will:

- Receive detailed information about this research study.
- Have a chance to ask and receive answers to any questions you may have.
- Be asked to read and sign and date this informed consent, once you understand the study and wish to take part.
- Be given a signed and dated copy of this informed consent to keep.

Taking part in this study is entirely voluntary.

WHY ARE THESE DRUGS BEING STUDIED?

Biological drugs are generally large, complex molecules that are often very expensive. There is need to bring more generic-like treatment options to patients that are called biosimilars. This study will characterize the effect that biological drugs (Evolocumab or Alirocumab) have on the body in order to be able to design studies to bring biosimilars for these drugs to the market. If you agree to participate in this study, you will be given either Evolocumab at a standard or subtherapeutic dose level, Alirocumab at a standard or subtherapeutic dose level, or a placebo. You will receive a single dose of one of the drugs or placebo. A placebo is a medically inactive substance which looks like the study drug. Subtherapeutic means it will be given at a lower dose than what is given to people who are being treated for the disease.

HOW WILL THIS STUDY BE DONE?

Once the study investigator determines that you are eligible to participate, you will be enrolled into one of the dosing groups below. You will not be allowed to choose your group.

You will go through the same tests and procedures described below for any of the study treatments you receive, but the length of study will be different depending on which group you are in.

Depending on which dose group you are assigned you will receive one of the following study treatments on one day:

- A: Evolocumab low dose (21mg) sub cutaneous injection
- B: Evolocumab fairly low dose (35mg) sub cutaneous injection
- C: Evolocumab fairly high dose (70mg) sub cutaneous injection
- D: Evolocumab high dose (140mg) sub cutaneous injection
- E: Alirocumab low dose (15mg) sub cutaneous injection
- F: Alirocumab fairly low dose (25mg) sub cutaneous injection
- G: Alirocumab fairly high dose (50mg) sub cutaneous injection
- H: Alirocumab high dose (100mg) sub cutaneous injection
- I: Placebo sub cutaneous injection

A sub cutaneous injection is given with a small needle under the skin of your upper arm.

You will not be given a dose of either Evolocumab or Alirocumab that is higher than previously tested and approved by the FDA.

You will not be told which dose you are given and the study investigator and research staff will not know either.

If you are given dose A, B, E, or F you will finish the study on day 42.

If you are given dose C or G you will finish the study on day 56.

If you are given dose D, H, or I you will finish the study on day 84.

WHO IS BEING ASKED TO TAKE PART IN THIS STUDY?

Approximately 72 healthy male and female adult subjects, who meet the requirements following a screening visit, will be enrolled in the study.

You have been asked to take part in this study because you are in general good health, are between 18 and 55 years of age, have no history of heart or liver disease, no history of allergies, no symptoms consistent with coronavirus disease of 2019 (COVID-19), no underlying medical conditions that put you at higher risk for COVID-19 complications, and have not participated in another research study for an experimental drug (or a medical device) within 30 days of the first dose of study drug.

HOW MUCH TIME IS REQUIRED TO TAKE PART IN THE STUDY?

If you decide to take part in the study, you will be asked to attend a screening visit. If you pass the screening visit, you will return to the clinic for one period of 8 days and 7 nights. When you have completed this inpatient period you will be asked to return to the clinic on the following days:

- If you are in study treatment group A, B, E or F after leaving Spaulding Clinical on day 7, you will return for 7 additional visits on days 7, 10, 14, 21, 28, 35 and 42.
- If you are in study treatment group C or G after leaving Spaulding Clinical on day 7, you will return for 8 additional visits on days 7, 10, 14, 21, 28, 35, 42 and 56.
- If you are in study treatment group D, H or I after leaving Spaulding Clinical on day 7, you will return for 10 additional visits on days 7, 10, 14, 21, 28, 35, 42, 56, 70 and 84.

The duration of your participation in the study from screening to final follow-up will be up to 105 days.

INFORMATION FOR FEMALE VOLUNTEERS

You should not screen for this study if:

- There is any possibility that you may become, or are pregnant,
- You have given birth in the last 3 months, or
- You are breast feeding.

You may screen for this study if:

- You have had a hysterectomy (uterus removed) or bilateral oophorectomy (ovaries removed), confirmed with documentation, or
- You are of post-menopausal age and have not had a menstrual period for 2 years, confirmed with hormone level at screening, or
- You have a vasectomized partner who has been documented to no longer produce sperm, or
- You are using TWO highly reliable methods of contraception to avoid pregnancy throughout the study and for 3 months after last study drug administration. Highly reliable methods of birth control include:

- hormonal implants/patch,
- oral hormonal contraceptives,
- injectable hormones,
- intra-uterine device (IUD),
- approved cervical ring,
- diaphragm with spermicide or condom (female or male) with spermicide

The use of spermicide alone and condom alone are not acceptable methods of contraception.

Except for continuous abstinence (no sexual intercourse with a male partner), no method of birth control can be considered 100% reliable in preventing pregnancy. Although the risk of becoming pregnant is low with many methods, unplanned pregnancies may occur with all birth control methods. Most occur because of improper or irregular use of the birth control method. If you are usually not sexually active but become sexually active, you must follow the advice documented above regarding contraceptive methods.

All females enrolled in this study will have a pregnancy test performed at screening, at check in on Day -1 and at the final follow up visit.

Please be aware that a pregnancy test may not be positive until 12 days after conception (fertilization of the egg by sperm). Therefore, if you do not follow the study birth control requirements and/or your birth control method has failed, you will not be able to count on a negative test to confirm that you are not pregnant.

If you know that you have not followed the study birth control requirements outlined above, then you must immediately inform us. You must not take any dose of the study drug if you have not followed these requirements. If you become pregnant, your pregnancy will be followed to document the outcome. All live births must be followed for a minimum of 30 days or until the first well-baby visit.

INFORMATION FOR MALE VOLUNTEERS

The effect of the study drug on male sperm is unknown. In rare cases, drugs may damage sperm in ways that affect a child that is fathered. Affected sperm may be present in the semen for about 2 months. Therefore, it is recommended to avoid fathering a child for 60 days after the last dose of the study drug.

Male subjects must ensure that TWO acceptable methods of contraception are used for the entire duration of the study, up to the study follow-up visit, if applicable.

Periodic abstinence and withdrawal are not acceptable methods of contraception.

HOW WILL YOU KNOW IF YOU ARE ELIGIBLE TO TAKE PART?

You will need to fast for at least 8 hours prior to your arrival at Spaulding Clinical Research, LLC. for your screening visit, meaning you should not eat any food and should only have water to drink.

At the beginning of the Screening visit, Informed Consent will be obtained.

Before starting the study, the following screening procedures will be performed:

- A complete medical history and physical examination (including height and weight measurements for Body Mass Index (BMI, a way to tell if your weight is proportional to your height).
- Assessment of blood pressure, respiratory rate, heart rate, and oral temperature.

- A complete history of relevant allergies or drug sensitivities.
- An electrocardiogram (ECG), (a painless recording of the electrical activity of your heart).
- You will be asked if you have taken any medication recently.
- You will be asked if you have been feeling ill recently.
- Clinical laboratory tests (urine and blood samples), including screening for drugs, alcohol, and pregnancy tests (all female subjects), and testing for HIV, hepatitis B and C. Positive results of HIV or hepatitis tests will be reported to local health authorities as required by state law.
- Blood collection to look at levels of proteins and other constituents of your blood.

If you meet the “entry criteria” of the study, according to the study investigator, you will be tested again when you are admitted to Spaulding Clinical Research, LLC. You will have the entry criteria reviewed again to ensure that you still are eligible for the study.

In addition, prior to admission you will have a diagnostic test performed to detect severe acute respiratory syndrome coronavirus 2 (called “coronavirus” from now on), which is the virus that causes COVID-19. Depending on the time required to return results, this may be performed ~2 days before check-in or may be performed on the check-in day. You will only be allowed to be admitted if your coronavirus test is negative. In addition, when entering the building for screening and check-in, triage for COVID-19 will take place. The exact details of what will occur at triage may change as additional information or testing is available, however as of now it is planned to include asking about any potential contacts with COVID-19, signs and symptoms associated with COVID-19, temperature monitoring and potentially antibody screening for coronavirus. You will have to return to the site for multiple outpatient visits as part of the study. Outpatient visits that require entering the building will also have COVID-19 triage. When outpatient visits only require a blood draw, this may be performed in a covered area outside the building.

WHAT TESTS AND PROCEDURES WILL BE USED IN THE STUDY?

Day -1 Check-in

Upon admission to Spaulding Clinical Research, LLC., you will be given an identity band to wear throughout your entire stay in the unit.

You will need to fast for at least 8 hours prior to your arrival meaning you should not eat any food and should only have water to drink.

The following admission procedures will be performed:

- Perform/review results from coronavirus test.
- Medical history updates.
- Physical examination.
- Clinical laboratory tests (urine and blood samples), including screening for drugs, alcohol, and pregnancy tests (all female subjects).
- Blood and urine collection to look at levels of proteins and other constituents of your blood and urine.
- Assessment of blood pressure, respiratory rate, heart rate, and oral temperature.
- An electrocardiogram (ECG), (a painless recording of the electrical activity of your heart).
- You will be asked for details of any medication taken since the screening or previous visit.
- You will be asked if you have been ill since the screening or previous visit.
- You will be asked if you complied with study restrictions.
- You will be provided meals (lunch, dinner, and a small snack).

Inclusion/Exclusion assessment and preparation for randomization. Randomization means that you will be assigned by chance, like the flip of a coin, to either study group.

The results from these tests will help the study staff determine whether you are still eligible to enter the study.

Study Treatment (Day 1)

- Randomization (assigned by chance to a dose group).
- Adverse event assessment (check for side effects) and changes in concomitant medications (medicines you are currently taking).
- Physical exam.
- Assessment of oral temperature, blood pressure, respiratory rate, and heart rate.
- Blood (fasting) and urine collection to look at levels of proteins and other constituents of your blood and urine.
- Administration of study drug.
- Meals (breakfast, lunch, dinner, and a small snack).
- Clinical laboratory tests (blood samples).
- ECG procedures.
- Pharmacokinetic (PK) blood sampling (blood samples for determination of study drug levels). Pharmacokinetics looks at how your body:
 - Takes the drug into your bloodstream.
 - Delivers the drug from the blood to other organs or tissues.
 - Breaks down or processes the drug.
 - Removes or eliminates the drug.

Day 2 to Day 6

- Adverse event assessment and changes in concomitant medications.
- Pharmacokinetic (PK) blood sampling.
- Blood collection (fasting) to look at levels of proteins and other constituents of your blood.
- Meals (breakfast, lunch, dinner, and a small snack).

Day 7

- Adverse event assessment and changes in concomitant medications.
- Pharmacokinetic (PK) blood sampling.
- Blood (fasting) and urine collection to look at levels of proteins and other constituents of your blood and urine.
- Assessment of blood pressure, heart rate, respiratory rate and oral temperature.
- Safety ECG procedures.
- Clinical laboratory tests (urine and blood samples) including screening for drugs and alcohol.
- Physical examination.
- You will be discharged from the unit following completion of all procedures on day 7.

Outpatient Visit Days 10, 14, 21, 28, and 35 (all subjects)

- Adverse event assessment and changes in concomitant medications.
- Pharmacokinetic (PK) blood sampling.

- Blood (fasting) and urine (day 28 only) collection to look at levels of proteins and other constituents of your blood and urine.
- Assessment of blood pressure, heart rate, respiratory rate, and oral temperature (day 28 only).
- Safety ECG procedures (day 28 only).
- Clinical laboratory tests (urine and blood samples) (day 28 only).
- Physical examination (day 28 only).

Outpatient Visit Day 42 (all subjects)

- Adverse event assessment and changes in concomitant medications.
- Pharmacokinetic (PK) blood sampling.
- Blood (fasting) collection to look at levels of proteins and other constituents of your blood.
- Subjects in study treatment groups **A, B, E, and F only**:
 - Assessment of blood pressure, heart rate, respiratory rate, and oral temperature.
 - Safety ECG procedures.
 - Urine collection to look at levels of proteins and other constituents of your urine.
 - Clinical laboratory tests (urine and blood samples) including screening for drugs and alcohol, and pregnancy tests (all female subjects).
 - Physical examination.

Outpatient Visit Day 56 (subjects in study treatment groups C, D, G, H, and I)

- Adverse event assessment and changes in concomitant medications.
- Pharmacokinetic (PK) blood sampling.
- Blood (fasting) collection to look at levels of proteins and other constituents of your blood.
- For study treatment groups **C and G only**:
 - Assessment of blood pressure, heart rate, respiratory rate, and oral temperature.
 - Safety ECG procedures.
 - Urine collection to look at levels of proteins and other constituents of your urine.
 - Clinical laboratory tests (urine and blood samples) including screening for drugs, alcohol, and pregnancy tests (all female subjects).
 - Physical examination.

Outpatient Visit Day 70 (subjects in study treatment groups D, H, and I)

- Adverse event assessment and changes in concomitant medications.
- Pharmacokinetic (PK) blood sampling.
- Blood collection (fasting) to look at levels of proteins and other constituents of your blood

Outpatient Visit Day 84 (subjects in study treatment groups D, H, and I)

- Adverse event assessment and changes in concomitant medications.
- Pharmacokinetic (PK) blood sampling.
- Blood (fasting) and urine collection to look at levels of proteins and other constituents of your blood and urine.
- Assessment of blood pressure, heart rate, respiratory rate, and oral temperature.
- Safety ECG procedures.
- Clinical laboratory tests (urine and blood samples) including screening for drugs, alcohol, and pregnancy tests (all female subjects).
- Physical examination.

INFORMATION OBTAINED DURING THE STUDY**Blood Sampling**

Blood samples will be collected for measurement of levels of Evolocumab or Alirocumab at the following times:

- Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 h; Day 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 35, 42, 56, 70, 84 for a total of approximately 22, 23, or 25 blood collections for determining study drug levels depending on which dose you are given.

Blood samples will be collected for measurement of proteins and other constituents of your blood at the following times:

- Day -1 (check-in); Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 h; Day 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 35, 42, 56, 70, 84 for a total of approximately 23, 24, or 26 blood collections for determining study drug levels depending on which dose you are given.

Blood samples will be collected for measurement of lipids (for example, cholesterol) in your blood at the following times:

- Day -1 (check-in); Day 1: 0 (pre-dose), 24 h; Day 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 35, 42, 56, 70, 84 for a total of approximately 15, 16, or 18 blood collections for determining study drug levels depending on which dose you are given.

You will have numerous blood samples drawn during the entire study for study drug levels as shown above, and up to 7 safety laboratory draws throughout the study. The blood samples may be taken by individual needle sticks into one of your arm veins, or, if necessary, by an indwelling catheter (a thin plastic tube placed in a vein in your arm).

The total amount of blood taken for the entire study will be:

- For study treatment groups A, B, E and F: approximately 350ml or almost 1 ½ cups for the entire study.
- For study treatment groups C and G: approximately 375ml or just over 1 ½ cups for the entire study.
- For study treatment groups D, H and I: approximately 415ml or approximately 1 ¾ cups for the entire study.

Some of the samples collected may undergo pharmacogenetic testing. Pharmacogenetics is the study of differences in how our bodies respond to or handle medicines. This research will look at genetic differences to better understand why people react or respond differently when they get the same medicine. Any personal health information about you, including any genetic information, will be kept confidential.

Urine Sampling

You will have urine samples collected at screening, Day -1 (Check In), the last study day and on four additional days during the study. These will be used to screen for either alcohol or drugs, for routine safety analysis, or assessment of your body's response to the drug.

ECG Measurements

Safety ECG measurements will occur at your screening visit, day -1, day 1, day 7, day 28, and at the end of study visit. There will be periods of time where you will need to lie very still to get precise readings of your heart's rhythm.

Some individuals may develop redness, irritation, or discoloration of the skin at the site of ECG electrodes placed on the chest/body. This may develop due to sensitivity to the electrodes or to our skin preparation procedure. In order to get the quality results we need, it is necessary for us to lightly scrub the skin with an abrasive pad to remove any skin impedance such as oil, dead skin cells and lotions. We may trace each electrode site with a permanent marker to assure electrodes are placed in the same place on the body for each ECG event to maintain quality and consistent results. This tracing may occur as often as once a day during confinement.

WHAT ARE YOUR RESTRICTIONS DURING THE STUDY?

You will need to avoid the following while taking part in this study, and most importantly from the time of your screening visit until you check in:

Restricted Item:	Duration:
Alcohol	48 hours before dose until the end of study visit
Caffeine or other xanthines (for example, coffee, tea, cola or chocolate)	48 hours before dose until the end of study visit
Grapefruit	48 hours before dose until the end of study visit
Prescription medication	14 days prior to dose
NSAIDs (Ibuprofen, Naproxen)	14 days prior to dose
Nicotine containing products	6 weeks prior to screening until end of study visit

You will receive a diet that does not contain any alcohol or caffeine. You must eat all of each meal that is served to you and eat at a reasonable pace (within 30 minutes).

You may eat only meals and snacks that are provided to you during the periods of your stay. After checking out of the clinic, there are no dietary restrictions aside from what is listed in the table above.

Due to current precautions being taken for COVID-19, the following restrictions will be in place:

- Subjects must always wear masks except when in a private room without anyone else present or for a limited time for a study procedure (for example, study drug administration or eating) when instructed by study staff.

- Subjects must practice social distancing, which will include having 1 subject per room for overnight stays and having common areas closed. Food will be served at subjects' rooms with subjects sitting at their doorway to eat. Subjects will spend most of their time in their rooms except for specified times for walking in the halls (with masks).
- Subjects must practice regular handwashing with soap and water, scrubbing hands for at least 20 seconds or with approved hand sanitizer as supplied by study staff.

If new information becomes available, there could be other precautions that lead to additional restrictions.

ARE THERE RISKS TO YOU IF YOU ARE IN THIS STUDY?

Please be advised that non-pharmacological treatments (such as heating pack, stretches, hydration, etc.) are our first line of therapy for mild adverse events. The study investigator will be notified if a concomitant medication may be needed to treat an adverse event. Following the study plan guidelines, the study investigator will assess your adverse event and develop a treatment plan.

Risks are possible side effects of the study drug, the positive control drug, and those of taking blood and other medical procedures:

For Evolocumab

- Upper respiratory tract infection
- Injection site reaction
- Back Pain
- Influenza
- Cough
- Headache
- Urinary Tract (bladder) infection
- Muscle Pain
- High Blood Pressure

For Alirocumab

- Upper respiratory tract infection
- Injection site reaction
- Back Pain
- Influenza (flu)
- Cough
- Headache
- Urinary Tract (bladder) infection
- Muscle Pain
- High Blood Pressure
- Diarrhea
- Bronchitis (lung infection)

Problems or side effects that are not now known could also occur. You will be given any new information that may affect your willingness to start or continue in the study.

The tests done at each visit are standard medical tests. The most unpleasant is often having blood samples taken. The risks of taking blood may include:

- Fainting
- Pain
- Bruising
- Rarely, there may be a small blood clot or infection at the site of the needle puncture

The blood pressure cuff may also cause discomfort or bruising to the upper arm.

In rare instances where a nurse, a investigator, or a technician, sustains an exposure to your blood, tissue or body fluids by needle stick, cut or splash to mucosa or damaged skin, it may be necessary to test your blood, tissue, or body fluid sample for certain viral infections including Hepatitis B and C and HIV on the sample already available. This is to enable that person to receive appropriate counseling, monitoring and treatment if necessary. In this instance, the study investigator or designee will offer you the information relevant to your health and advise you on the next steps. Confidentiality of your data will be respected at all times according to the state law.

Unknown Risks

As with any drug, it is possible that you could experience an allergic reaction to the study drug used in this study. Symptoms of any allergic reaction can include:

- Rash
- Hives
- Itching
- Difficulty breathing
- Closing of the throat
- Swelling of the lips, tongue or face
- Rarely, death.

If you think you are having a severe allergic reaction, while outside the study center call 9-1-1 and seek medical attention immediately.

It is very important that you tell the study investigator and the study staff about any side effects that you might experience.

You may experience side effects or discomforts that are not listed on this form. Tell your study investigator or study staff immediately if you have any problems. Your safety will be closely monitored throughout the study.

For ECG Monitoring

It is possible to be sensitive to the adhesives used on the electrodes that are applied to your chest when having an ECG performed. If this is the case, you could develop a temporary redness, irritation, or discoloration of the skin where the electrodes were applied.

HIV and Hepatitis B and C Testing

The risks of HIV and Hepatitis B and C testing include psychological and social risks. A positive test can lead to restrictions in freedom of travel to some countries and possible prejudices in job employment, insurance eligibility, housing and other forms of discrimination. Positive HIV and Hepatitis B and C test

results must be reported to health authorities under state law. A positive HIV and/or Hepatitis B or C result will exclude you from participation in the study.

Reproductive Risks

The effects of the study drug on human pregnancy and the unborn child (fetus) are unknown. Therefore, it is very important that you do everything within your power not to become pregnant, or father a child during this study and for 60 days following the last dose. Please ensure that you follow the study birth control requirements outlined in the sections regarding information for male and female subjects above.

If you become pregnant during the course of the study, you will be withdrawn from the study immediately. Neither Spaulding Clinical Research, LLC. nor the sponsor will be responsible for the cost of any obstetric or related care, or for your child's care. Female subjects are agreeing, by signing and dating this form, that information about your pregnancy and birth of your child may be collected. The information collected will include your health and the health of your unborn child during pregnancy, pregnancy outcome (miscarriage, termination, live birth, etc.), and the health of the baby after it is born (for a minimum of 30 days after delivery or until the first well baby visit).

Partners of male subjects who become pregnant will be asked to sign a separate consent form to allow collection of the information listed above. Your information will be kept confidential in accordance with state and Health Insurance Portability and Accountability Act of 1996 (HIPAA) law. See Agreement at the end of the consent form.

COVID-19 Risks

Despite the extra precautions (for example COVID-19 triage at screening/check-in, coronavirus testing, mandatory masks for study subjects and staff, social distancing including single-occupancy rooms, extra hand washing) that will be in place, there is still a risk of developing COVID-19 just as there is when you are not at Spaulding Clinical. Tell your study doctor or study staff about any new symptoms you develop during the study.

The U.S. Centers for Disease Control and Prevention (CDC) currently highlights that people with the following symptoms may have COVID-19:

- Cough
- Shortness of breath or difficulty breathing

Or at least two of these symptoms:

- Fever
- Chills
- Repeated shaking with chills
- Muscle pain
- Headache
- Sore throat
- New loss of taste or smell

It is important to note that COVID-19 can also present with other symptoms and just because you develop any of the above symptoms does not mean that you have COVID-19. Your study doctor will evaluate if your symptoms warrant additional testing, further isolation from other study subjects/staff until testing results are obtained, and any treatment.

NEW FINDINGS

Your study investigator will tell you of any information learned during the course of the study that might cause you to change your mind about taking part in the study. You may contact the study investigator at any time after your participation ends to find out if any new information about this study has become available.

WHAT IS THE ALTERNATIVE TO BEING IN THE STUDY?

Since this is a study involving healthy volunteers, your alternative is not to take part.

WILL YOU BENEFIT FROM TAKING PART IN THE STUDY?

You will not receive direct medical benefit from receiving the study drug. You may benefit by having your medical history recorded, undergoing a physical examination, and having blood and urine tests as they apply to this research project.

Just by taking part in this research study, you may be helping future patients by providing important information about the study drug and by contributing to medical knowledge.

WHO IS PAYING FOR THIS STUDY?

The US Food and Drug Administration is the Sponsor of the study.

The US Food and Drug Administration pays the study investigator to run this study.

The study drug and all tests, procedures and visits required by the study are provided at no cost to you. The sponsor, the US Food and Drug Administration pays for them.

Information about this study is confidential. This information belongs to the US Food and Drug Administration. We ask that you keep it private. You can discuss this information in private with your investigator or family to talk about your healthcare or to decide about taking part in this study.

WILL YOU BE PAID FOR BEING IN THIS STUDY?

Compensation for screening is as follows:

- \$55.00 if you qualify and take part in a study. \$55.00 for your time and inconvenience if you do not qualify for a study.
- If the results of the drug and alcohol tests are positive, or if you attempt to falsify your drug screen you will not receive any compensation.
- If you screen for the study, qualify and are enrolled, your screening payment will be included in your first stipend payment. If you are not accepted into the study your screening payment will be processed and mailed within 7 calendar days of study enrollment.

Compensation for this study is as follows:

For subjects in dose groups A, B, E or F that complete the entire study (Day -1 to Day 42), you will receive up to \$6,500.00. This payment will be made in four separate payments as follows:

- \$3000.00 will be paid after all check out procedures have been completed at the end of day 6,

- \$1500.00 will be paid after all procedures have been completed at the end of day 28,
- \$1500.00 will be paid after all procedures have been completed at the end of day 42.
- The remaining \$500 will be paid after the follow up visit/call, and any additional follow up procedures are completed, and all results are reviewed.

For subjects in dose groups C or G that complete the entire study (Day -1 to Day 56), you will receive up to \$6,600.00. This payment will be made in four separate payments as follows:

- \$3000.00 will be paid after all check out procedures have been completed at the end of day 6,
- \$1500.00 will be paid after all procedures have been completed at the end of day 28,
- \$1500.00 will be paid after all procedures have been completed at the end of day 56.
- The remaining \$600 will be paid after the follow up visit/call, and any additional follow up procedures are completed, and all results are reviewed.

For subjects in dose groups D, H or I that complete the entire study (Day -1 to Day 84), you will receive up to \$6,800.00. This payment will be made in four separate payments as follows:

- \$3000.00 will be paid after all check out procedures have been completed at the end of day 6,
- \$1500.00 will be paid after all procedures have been completed at the end of day 28,
- \$1500.00 will be paid after all procedures have been completed at the end of day 84.
- The remaining \$800 will be paid after the follow up visit/call, and any additional follow up procedures are completed, and all results are reviewed.

If you withdraw from the study early, you will only be paid for the visits you completed. You will receive \$100.00 for each full day that you were in-house.

NOTE: You may be required to return to the clinic for repeat blood test or other assessments (ECG, physical, vital signs) in between periods or after the final check out. This is considered part of the study and no additional compensation is available. Your final payment will not be released until all follow up procedures have been completed and accepted by the study investigator. Once follow up procedures have been completed and accepted by study investigator, your final payment will be processed and mailed within 14 calendar days.

NOTE: If you meet eligibility criteria you may be asked to be an alternate subject. Alternate subjects are eligible subjects that are in addition to the number of subjects in the event an enrolled subject drops out before their dose can take place or in the event it is not safe for a subject to move forward with dosing. If you are selected as an alternate subject and you agree to participate as an alternate subject, you may receive up to \$250 if you are not needed to dose. If you are needed to replace a subject, you will be paid as stated for participating in and completing the study. If you agree to be an alternate subject, you will have all of the predose procedures as the enrolled subjects so that if you are needed, you will be ready to participate. If you are not needed you will be discharged shortly after completion of the dosing round.

No deductions for any state or federal withholding or any other similar taxes will be made and you are solely responsible for reporting such payments on your state and federal income tax returns.

If you need to stay at Spaulding Clinical Research, LLC. for a longer period of time for safety reasons, you will be compensated at a rate proportional to the entire compensation for the study.

If you are dismissed from the study for medical reasons OR if the study is temporarily or permanently halted, your compensation will be proportional to the time you spend in the study.

If you are dismissed from the study because you have not complied with the instructions of the study staff, no compensation is available. Non-compliance includes, but is not limited to, improper conduct, taking alcohol and/or any drugs (including recreational drugs), tampering with the study drug, or consuming any foods/beverages not allowed in the study.

Subjects may be reimbursed for travels expenses depending on need and Sponsor approval.

By signing and dating this consent, you expressly agree that you are an Independent Contractor for Spaulding Clinical Research, LLC. As an Independent Contractor, you will receive a 1099 form from Spaulding Clinical Research, LLC. The 1099 form shall document and report all payments and/or study stipends you received as an Independent Contractor for Spaulding Clinical Research, LLC. In addition, because you are an Independent Contractor and will be receiving payments and/or study stipends, those earnings are subject to wage garnishment. If Spaulding Clinical receives an Earnings Garnishment Notice (or similar) from a State or Federal legal entity, we will adhere to that garnishment.

COMPENSATION FOR INJURY

It is important that you follow carefully all the instructions given by the study investigator and his/her study staff regarding this study.

If you become ill or are physically injured as a result of participation in this study, please contact the study investigator right away at the telephone number listed on page one of this consent form. He/she will treat you or refer you for treatment.

Spaulding Clinical Research, LLC. and/or its affiliated institutions has not set aside funds to provide you with financial compensation or reimbursement for the cost of care provided to treat a research-related injury or for other expenses arising from a research-related injury. You or your insurer will be responsible for the payment of any medical treatments for research related injuries or illness. By signing and dating this consent form, you are not giving up any legal rights. If this research study is conducted in a negligent manner and you are injured as a direct result, you may be able to recover the costs of care and other damages from the individuals or organizations responsible for your injury as you still have the right to seek compensation for injury related to malpractice, negligence, fault, guilt or blame of those involved in the research.

PROTECTING THE PRIVACY OF YOUR HEALTH DATA

Unless required by law, your name will not be disclosed outside the research clinic. Your name will be available only to the following people or agencies: the study investigator and study staff; and authorized representatives of the study investigator; institutional review board (IRB), health authority inspectors, such as the US Food & Drug Administration and the European Medicines Agency; the US Food and Drug Administration, study monitors and auditors; and authorized Clinical Research Organization representatives. The above mentioned individuals will use the personal information collected as part of this study, including your medical records (“Study Information”) to check that the study is conducted correctly and to ensure the accuracy of the study information. These people are all obligated to maintain confidentiality by the nature of their work, or are bound by confidentiality agreements. If required, the study investigator may contact your personal investigator to collect additional medical information and your past medical history.

The study investigator may only share your study information with people whom you have permitted to see it. However once your study information is shared as authorized, it may no longer be protected by Federal law and may be re-disclosed without your permission.

While participating in this study, the study investigator will replace your name with a special code that identifies you. This code, along with your study information, will be used by the study sponsor, the US Food and Drug Administration and their representatives, for the study purposes mentioned above and to help establish whether the study drug is safe and effective. The US Food and Drug Administration may share your coded information, as necessary, with the US Food and Drug Administration affiliates who work within the scope of this consent; people and companies who work with the US Food and Drug Administration and who work within the scope of this consent; Ethics committees and Regulatory agencies such as the US Food & Drug Administration, the National Health Authorities, and the European Medicines Agency.

You should be aware that some countries may not offer the same level of privacy protection as you are used to in the country where you live or where this study is conducted. However, the US Food and Drug Administration will keep any information it receives to the same standard of confidentiality as far as permitted by applicable local law. The US Food and Drug Administration has also entered into agreements with third parties working for the US Food and Drug Administration to secure adequate protection of your data and samples.

The Study Information will be kept confidential within the limits of the law and used only for research purposes mentioned above. De-identified data (data not linked to you) from the study may be released to a data warehouse (location that will store the data) or as a part of a publication. Research may be performed by researchers outside of the FDA and Spaulding Clinical Research, LLC. If the results of this study are published or presented in a meeting, you will not be named and no one will be able to tell that you were in the study from the publication or presentation.

Your participation in this study is voluntary and you may cancel this consent at any time and without any reason. If you do so, your participation in the study will end and the study staff will stop collecting information from you, however, you will be asked to come back to the site for an end of study visit. Your samples will then be destroyed. However, the US Food and Drug Administration will continue to retain and use any research results that have already been collected to verify the scientific integrity of the study. If you wish to leave the study inform your study investigator.

You have the right to review your Study Information and medical records and request changes to the Study Information if it is not correct. However, please note that during the study, access to Study

Information may be limited if it weakens the integrity of the research. You may have access to the Study Information held by the study investigator at the end of the study.

If you have any questions about the collection and use of information about you, or would like to exercise rights that you may have regarding this information, you should ask your study investigator.

WHOM TO CONTACT ABOUT THIS STUDY

During the study, if you experience any medical problems, suffer a research-related injury, or have questions, concerns or complaints about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. If you seek emergency care, or hospitalization is required, alert the treating physician that you are participating in this research study.

An institutional review board (IRB) is an independent committee established to help protect the rights of research subjects. If you have any questions about your rights as a research subject, and/or concerns or complaints regarding this research study, contact:

- By mail:
Study Subject Adviser
Advarra IRB
6940 Columbia Gateway Drive, Suite 110
Columbia, MD 21046
- or call **toll free:** 877-992-4724
- or by **email:** adviser@advarra.com

Please reference the following number when contacting the Study Subject Adviser: Pro00040438.

IS YOUR PARTICIPATION VOLUNTARY?

Yes, your participation in this study is strictly voluntary. You may refuse to take part in it, or you may stop participating at any time, even after signing and dating this informed consent. There will be no penalty or loss of benefits to which you are otherwise entitled. However, if you decide to leave the study before it ends, the study investigator will need to see you before you are released from the study.

The study investigator, Sponsor, FDA or Advarra may also decide to remove you from the study at any time without your consent. The study investigator may choose to take you out of the study because of unexpected or serious side effects, or for other scientific, technical, or safety considerations.

Examples why you may be taken out of the study are:

- Staying in the study would be harmful
- You need treatment not allowed in this study
- You failed to follow instructions
- You become pregnant
- The study is cancelled
- Your study treatment arm is stopped

If your participation ends for any reason, you will return to the study for the following study procedures:

- Physical examination.
- Pregnancy test (if necessary).
- Body weight and body temperature.
- Blood pressure and pulse rate.
- ECG.
- Blood draws for hematology and chemistry.
- Blood draws for PK.
- Urine will be collected for urinalysis.
- Adverse events and concomitant medications.

If you should decide to leave the study you should tell the study investigator or study staff. They will make sure that proper procedures are followed and a final visit is made for your safety.

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

STATEMENT OF CONSENT

I have read this form and its contents were explained to me. I agree to be in this research study for the purposes listed above. All my questions were answered to my satisfaction. I will receive a signed and dated copy of this form for my records. I am not giving up any of my legal rights by signing and dating this form.

Signature of Research Subject

____/____/____
Date

Printed Name of Research Subject

Time (24hr)

STATEMENT OF PERSON OBTAINING INFORMED CONSENT

I have carefully explained to the subject the nature and purpose of the above study. There has been an opportunity for the subject to ask questions about this research study. I have been available to answer any questions that the subject has about this study.

Initials of Person Obtaining Informed Consent

____/____/____
Date

HIPAA Authorization Agreement Permission to Review, Use and Release Information about You

If you decide to be in this study, the study investigator and research team will use and share health data about you to conduct the study. Health data may include:

- Your name.
- Address.
- Phone number.
- Date of birth.
- Medical history.
- Information from your study visits, including all test results.

Health data may come from your study records or from existing records kept by your investigator or other health care workers.

For this study, the research team may share health data about you with authorized users. Authorized users may include:

- Representatives of the US Food and Drug Administration
- Representatives of Spaulding Clinical Research, LLC.
- Representatives of Advarra (a Research Ethics Review Board that reviews this study).
- The Food and Drug Administration (FDA) and other US governmental agencies.
- Government agencies to whom certain diseases (like HIV, hepatitis, and STIs) must be reported.
- Governmental agencies of other countries.
- Labs working with the sponsor on this study.
- Other authorized users.

The sponsor and those working for the sponsor may use the health data sent to them:

- To see if the study drug works and is safe.
- To compare the study drug to other drugs.
- For other research activities related to the study drug.

Once your health data has been shared with authorized users, it may no longer be protected by federal privacy laws.

Your permission to use and share health data about you will not end unless required by state law. If state law applies, your permission to use and share health data about you will end in 50 years unless you revoke it (take it back) sooner.

You may take back your permission to use and share health data about you at any time by writing to the study investigator at the address listed on page one of this consent form. If you do this, you will not be able to stay in this study. No new health data that identifies you will be gathered after your written request is received. However, health data about you that has already been gathered may still be used and given to others as described in this form.

Your right to access your health data in the study records will be suspended during the study to keep from changing the study results. When the study is over, you can access your study health data.

If you decide not to sign and date this form, you will not be able to take part in the study.

STATEMENT OF AUTHORIZATION

I have read this form and its contents were explained. My questions have been answered. I voluntarily agree to allow study staff to collect, use and share my health data as specified in this form. I will receive a signed and dated copy of this form for my records. I am not giving up any of my legal rights by signing and dating this form.

Signature of Research Subject

____/____/____
Date

Printed Name of Research Subject

STATEMENT OF PERSON OBTAINING AUTHORIZATION

I have carefully explained to the subject the nature and purpose of this form. I have been available to answer any questions that the subject has about this form.

Initials of Person Obtaining Authorization

____/____/____
Date